HaploX aims to integrate liquid biopsy technology, gene sequencing, artificial intelligence, big data, and other technologies to improve the management of cancer patients.
A group of investors including SBCVC and Kexin Capital have backed a $32 million funding round for China’s HaploX Biotechnology. ,Greater China,Healthcare,Technology,Early-stage ,China,Softbank China Venture Capital,Venture
